Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC

被引：0

作者：

Deininger, Michael

Apperley, Jane

Arthur, Christopher Kevin

Chuah, Charles

Hochhaus, Andreas

de Lavallade, Hugues

Lipton, Jeffrey Howard

Lomaia, Elza

McCloskey, James K.

Maness, Lori J.

Mauro, Michael J.

Moiraghi, Beatriz

Pavlovsky, Carolina

Rosti, Gianantonio

Rousselot, Philippe

Sutton, Maria Undurraga

Ren, Xiaowei

Vorog, Alexander

Kantarjian, Hagop M.

Cortes, Jorge E.

机构：

[1] Versiti Blood Res Inst, Milwaukee, WI USA

[2] Imperial Coll London, London, England

[3] Royal North Shore Hosp, St Leonards, NSW, Australia

[4] Duke NUS Med Sch, Singapore Gen Hosp, Singapore, Singapore

[5] Univ Klinikum Jena, Jena, Germany

[6] Kings Coll Hosp NHS Fdn, London, England

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Almazov Natl Med Res Ctr, St Petersburg, Russia

[9] Hackensack Meridian Hlth, John Theurer Canc Ctr, Hackensack, NJ USA

[10] Univ Nebraska Med Ctr, Omaha, NE USA

[11] Mem Sloan Kettering, New York, NY USA

[12] Hosp Jose Maria Ramos Mejia, Buenos Aires, DF, Argentina

[13] Fundaleu, Buenos Aires, DF, Argentina

[14] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, FC, Italy

[15] Ctr Hosp Versailles Univ Versailles St Quentin En, Paris, France

[16] Hosp Salvador, Santiago, Chile

[17] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

[19] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6501

引用

页数：1

共 50 条

[1] 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study
Deininger, Michael
Apperley, Jane
Arthur, Christopher Kevin
Chuah, Charles
Hochhaus, Andreas
de Lavallade, Hugues
Lipton, Jeffrey
Lomaia, Elza
McCloskey, James
Maness, Lori
Mauro, Michael
Moiraghi, Beatriz
Pavlovsky, Carolina
Rosti, Gianantonio
Rousselot, Philippe
Sutton, Maria Undurraga
Ren, Xiaowei
Vorog, Alexander
Kantarjian, Hagop
Cortes, Jorge
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S354
[2] Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Jabbour, Elias
Apperley, Jane
Cortes, Jorge
Rea, Delphine
Deininger, Michael
Abruzzese, Elisabetta
Chuah, Charles
Deangelo, Daniel J.
Hochhaus, Andreas
Lipton, Jeffrey H.
Mauro, Michael
Nicolini, Franck
Pinilla-Ibarz, Javier
Rosti, Gianantonio
Rousselot, Philippe
Shah, Neil P.
Talpaz, Moshe
Vorog, Alexander
Ren, Xiaowei
Kantarjian, Hagop
LEUKEMIA, 2024, 38 (03) : 475 - 481
[3] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
Talpaz, Moshe
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale L.
Flinn, Ian
O'Hare, Thomas J.
Hu, Simin
Rivera, Victor M.
Clackson, Timothy Piers
Conlan, Maureen G.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W. N.
Mauro, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Jabbour, Elias
Apperley, Jane
Cortes, Jorge
Rea, Delphine
Deininger, Michael
Abruzzese, Elisabetta
Chuah, Charles
Deangelo, Daniel J.
Hochhaus, Andreas
Lipton, Jeffrey H.
Mauro, Michael
Nicolini, Franck
Pinilla-Ibarz, Javier
Rosti, Gianantonio
Rousselot, Philippe
Shah, Neil P.
Talpaz, Moshe
Vorog, Alexander
Ren, Xiaowei
Kantarjian, Hagop
LEUKEMIA, 2024, 38 (10) : 2291 - 2291
[5] COST-EFFECTIVENESS ANALYSIS OF PONATINIB IN THE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SWEDEN
Iannazzo, S.
McGarry, L.
Chiroli, S.
VALUE IN HEALTH, 2015, 18 (07) : A668 - A668
[6] Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib
Nickel, Robert Sheppard
Daves, Marla
Keller, Frank
PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 2050 - 2051
[7] T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia
Kimura, Kenji
Tsukamoto, Shokichi
Takaishi, Koji
Isshiki, Yusuke
Kayamori, Kensuke
Hino, Yutaro
Ohshima-Hasegawa, Nagisa
Mitsukawa, Shio
Takeda, Yusuke
Mimura, Naoya
Takeuchi, Masahiro
Ohwada, Chikako
Iseki, Tohru
Nakaseko, Chiaki
Sakaida, Emiko
LEUKEMIA & LYMPHOMA, 2019, 60 (06) : 1591 - 1594
[8] Asciminib Management in Chronic Myeloid Leukemia (CML) Patients With T315I Mutation
Kuzmina, Elena
Lomaia, Elza
Morozova, Elena
Chelysheva, Ekaterina
Shukhov, Oleg
Petrova, Anna
Chitanava, Tamara
Vlasova, Yulia
Sbityakova, Evgenia
Makarova, Tayana
Nemchenko, Irina
Bykova, Anastasiya
Gurianova, Margarita
Julhakyan, Hunan
Kokhno, Alina
Turkina, Anna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S334 - S334
[9] Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML)
Chomel, Jean-Claude
Sorel, Nathalie
Bonnet, Marie-Laure
Bertrand, Angelina
Brizard, Francoise
Saulnier, Pierre-Jean
Roy, Lydia
Guilhot, Francois
Turhan, Ali G.
LEUKEMIA RESEARCH, 2009, 33 (04) : 551 - 555
[10] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
Talpaz, M.
Cortes, J. E.
Kantarjian, H. M.
Shah, N. P.
Bixby, D. L.
Flinn, I. W.
O'Hare, T. J.
Hu, S.
Rivera, V. M.
Clackson, T.
Conlan, M. G.
Haluska, F. G.
Druker, B. J.
Deininger, M. W.
Mauro, M. J.
HAEMATOLOGICA, 2015, 100 : 65 - 66

← 1 2 3 4 5 →